Recent advances in the pathophysiologic understanding of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe …

Polycythaemia vera is associated with a reduced quality of life, a high rate of vascular
events, and an intrinsic risk of disease evolution. The results of several randomised trials for …

Increasing number of Janus kinase (JAK) inhibitors have been approved for chronic
haematopoietic neoplasms and inflammatory/autoimmune diseases. We aimed to assess …

Accumulating data on cellular and molecular pathways help to develop novel therapeutic
strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic …

The JAK-STAT signaling pathway plays a central role in signal transduction in hematopoietic
cells, as well as in cells of the immune system. The occurrence in most patients affected by …

Clonal alterations in hematopoietic cells occur during aging and are often associated with
the establishment of a subclinical inflammatory environment. Several age-related conditions …

A multitude of new agents for the treatment of hematologic malignancies has been
introduced over the past decade. Hematologists, infectious disease specialists, stem cell …

Background After discontinuing ruxolitinib, the outcome of patients with myelofibrosis
reportedly has been poor. The authors investigated whether disease characteristics before …

Unleashing antitumor T cell activity by checkpoint inhibitor immunotherapy is effective in
cancer patients, but clinical responses are limited. Cytokine signaling through the Janus …

Type 2 immunity evolved to combat helminth infections by orchestrating a combined
protective response of innate and adaptive immune cells and promotion of parasitic worm …